Apex Biotechnology Corp. (TPE:1733)

Market Cap	3.12B +6.7%
Revenue (ttm)	1.87B -8.2%
Net Income	190.27M +17.3%
EPS	1.89 +17.5%
Shares Out	99.95M
PE Ratio	16.53
Forward PE	n/a
Dividend	1.30 (4.19%)
Ex-Dividend Date	Jun 9, 2026

Volume	73,880
Open	31.30
Previous Close	31.25
Day's Range	31.10 - 31.30
52-Week Range	28.00 - 38.70
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Apex Biotechnology

Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. It offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing systems. The company also provides pesticide residue check systems; and care management and tele-health services. The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1733

Financial Performance

In 2025, Apex Biotechnology's revenue was 1.94 billion, an increase of 5.00% compared to the previous year's 1.85 billion. Earnings were 162.89 million, an increase of 27.26%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error